ATAD3B

Across TCGA pan-cancer cohorts, ATAD3B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATAD3B data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATAD3B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATAD3B expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where ATAD3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.890	0.605	.008	15	view →
LUAD	OS	Tertile	II,III,IV	0.318	1.000	.024	12	view →
LSCC	DFS	Median	III,IV	0.817	0.370	.021	9	view →
OV	DFS	Tertile	All	0.580	1.000	.041	8	view →
PDAC	DFS	Tertile	IV	0.515	0.182	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATAD3B–HNSC (DFS)

Open the HNSC breakdown →